Literature DB >> 32113132

DNA-PKcs chemical inhibition versus genetic mutation: Impact on the junctional repair steps of V(D)J recombination.

Z Anne Esguerra1, Go Watanabe1, Cindy Y Okitsu2, Chih-Lin Hsieh2, Michael R Lieber3.   

Abstract

Spontaneous DNA-PKcs deficiencies in animals result in a severe combined immunodeficiency (SCID) phenotype because DNA-PKcs is required to activate Artemis for V(D)J recombination coding end hairpin opening. The impact on signal joint formation in these spontaneous mutant mammals is variable. Genetically engineered DNA-PKcs null mice and cells from them show a >1,000-fold reduction in coding joint formation and minimal reduction in signal joint formation during V(D)J recombination. Does chemical inhibition of DNA-PKcs mimic this phenotype? M3814 (also known as Nedisertib) is a potent DNA-PKcs inhibitor. We find here that M3814 causes a quantitative reduction in coding joint formation relative to signal joint formation. The sequences of signal and coding junctions were within normal limits, though rare coding joints showed novel features. The signal junctions generally did not show evidence of resection into the signal ends that is often seen in cells that have genetic defects in DNA-PKcs. Comparison of the chemical inhibition findings here with the known results for spontaneous and engineered DNA-PKcs mutant mammals is informative for considering pharmacologic small molecule inhibition of DNA-PKcs in various types of neoplasia.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Artemis; Immunoglobulin gene rearrangement; Site-Specific recombination; V(D)J recombination

Mesh:

Substances:

Year:  2020        PMID: 32113132      PMCID: PMC7184946          DOI: 10.1016/j.molimm.2020.01.018

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  36 in total

1.  Distinct effects of DNA-PKcs and Artemis inactivation on signal joint formation in vivo.

Authors:  Cédric Touvrey; Chrystelle Couedel; Pauline Soulas; Rachel Couderc; Maria Jasin; Jean-Pierre de Villartay; Patrice N Marche; Evelyne Jouvin-Marche; Serge M Candéias
Journal:  Mol Immunol       Date:  2008-05-23       Impact factor: 4.407

2.  Purification and characterization of the double-stranded DNA-activated protein kinase, DNA-PK, from human placenta.

Authors:  D W Chan; C H Mody; N S Ting; S P Lees-Miller
Journal:  Biochem Cell Biol       Date:  1996       Impact factor: 3.626

3.  Binding of inositol hexakisphosphate (IP6) to Ku but not to DNA-PKcs.

Authors:  Yunmei Ma; Michael R Lieber
Journal:  J Biol Chem       Date:  2002-01-30       Impact factor: 5.157

4.  Autosomal recessive severe combined immunodeficiency of Jack Russell terriers.

Authors:  Thomas G Bell; Kelly L Butler; Helen B Sill; Julia E Stickle; Jose A Ramos-Vara; Michael J Dark
Journal:  J Vet Diagn Invest       Date:  2002-05       Impact factor: 1.279

Review 5.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway.

Authors:  Michael R Lieber
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

6.  A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.

Authors:  Mirjam van der Burg; Hanna Ijspeert; Nicole S Verkaik; Tuba Turul; Wouter W Wiegant; Keiko Morotomi-Yano; Pierre-Olivier Mari; Ilhan Tezcan; David J Chen; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

7.  The defect in murine severe combined immune deficiency: joining of signal sequences but not coding segments in V(D)J recombination.

Authors:  M R Lieber; J E Hesse; S Lewis; G C Bosma; N Rosenberg; K Mizuuchi; M J Bosma; M Gellert
Journal:  Cell       Date:  1988-10-07       Impact factor: 41.582

Review 8.  DNA-PKcs deficiency in human: long predicted, finally found.

Authors:  Mirjam van der Burg; Jacques J M van Dongen; Dik C van Gent
Journal:  Curr Opin Allergy Clin Immunol       Date:  2009-12

9.  Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.

Authors:  Justin J J Leahy; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Caroline Richardson; Laurent Rigoreau; Graeme C M Smith
Journal:  Bioorg Med Chem Lett       Date:  2004-12-20       Impact factor: 2.823

10.  CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro.

Authors:  Toshiya Tsuji; Lisa M Sapinoso; Tam Tran; Bonny Gaffney; Lilly Wong; Sabita Sankar; Heather K Raymon; Deborah S Mortensen; Shuichan Xu
Journal:  Oncotarget       Date:  2017-08-18
View more
  5 in total

Review 1.  The molecular basis and disease relevance of non-homologous DNA end joining.

Authors:  Bailin Zhao; Eli Rothenberg; Dale A Ramsden; Michael R Lieber
Journal:  Nat Rev Mol Cell Biol       Date:  2020-10-19       Impact factor: 94.444

2.  Structural analysis of the basal state of the Artemis:DNA-PKcs complex.

Authors:  Go Watanabe; Michael R Lieber; Dewight R Williams
Journal:  Nucleic Acids Res       Date:  2022-07-22       Impact factor: 19.160

3.  Structural analysis of the catalytic domain of Artemis endonuclease/SNM1C reveals distinct structural features.

Authors:  Md Fazlul Karim; Shanshan Liu; Adrian R Laciak; Leah Volk; Mary Koszelak-Rosenblum; Michael R Lieber; Mousheng Wu; Rory Curtis; Nian N Huang; Grant Carr; Guangyu Zhu
Journal:  J Biol Chem       Date:  2020-06-23       Impact factor: 5.157

4.  Staring at the Naked Goddess: Unraveling the Structure and Reactivity of Artemis Endonuclease Interacting with a DNA Double Strand.

Authors:  Cécilia Hognon; Antonio Monari
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 5.  Programmed DNA Damage and Physiological DSBs: Mapping, Biological Significance and Perturbations in Disease States.

Authors:  Sara Oster; Rami I Aqeilan
Journal:  Cells       Date:  2020-08-10       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.